Medpace Holdings, Inc. (NASDAQ:MEDP) Shares Sold by EMC Capital Management

EMC Capital Management cut its holdings in shares of Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) by 67.5% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 813 shares of the company's stock after selling 1,687 shares during the period. EMC Capital Management's holdings in Medpace were worth $270,000 as of its most recent SEC filing.

Several other hedge funds have also made changes to their positions in the business. Gries Financial LLC acquired a new stake in Medpace during the 4th quarter worth approximately $212,000. Swedbank AB raised its stake in shares of Medpace by 245.5% in the fourth quarter. Swedbank AB now owns 77,400 shares of the company's stock valued at $25,715,000 after acquiring an additional 55,000 shares in the last quarter. R Squared Ltd purchased a new position in Medpace in the fourth quarter valued at $30,000. Pacer Advisors Inc. boosted its holdings in Medpace by 40.8% in the fourth quarter. Pacer Advisors Inc. now owns 12,485 shares of the company's stock valued at $4,148,000 after purchasing an additional 3,616 shares during the period. Finally, Blue Trust Inc. grew its stake in Medpace by 21.5% during the 4th quarter. Blue Trust Inc. now owns 808 shares of the company's stock worth $270,000 after purchasing an additional 143 shares in the last quarter. Institutional investors and hedge funds own 77.98% of the company's stock.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on MEDP shares. Truist Financial decreased their price objective on Medpace from $415.00 to $397.00 and set a "hold" rating for the company in a research note on Monday, October 14th. TD Cowen lowered their price target on shares of Medpace from $413.00 to $372.00 and set a "buy" rating for the company in a report on Wednesday, October 23rd. Robert W. Baird raised their price objective on shares of Medpace from $354.00 to $362.00 and gave the company a "neutral" rating in a report on Monday, January 27th. Redburn Atlantic started coverage on shares of Medpace in a research note on Monday, October 14th. They set a "buy" rating and a $404.00 target price for the company. Finally, William Blair reaffirmed an "outperform" rating on shares of Medpace in a report on Tuesday, October 22nd. Seven investment analysts have rated the stock with a hold rating and five have given a buy rating to the company's stock. According to MarketBeat.com, the company has a consensus rating of "Hold" and a consensus price target of $381.44.

Medpace Stock Down 1.8 %

NASDAQ:MEDP traded down $6.42 during mid-day trading on Monday, reaching $342.73. 147,737 shares of the stock were exchanged, compared to its average volume of 208,663. The stock has a market capitalization of $10.65 billion, a P/E ratio of 30.12, a P/E/G ratio of 1.79 and a beta of 1.36. Medpace Holdings, Inc. has a 1 year low of $291.15 and a 1 year high of $459.77. The company has a 50 day simple moving average of $342.50 and a 200-day simple moving average of $351.36.

About Medpace

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.